SGK2 mediates apoptosis in herpes simplex keratitis by suppressing protective autophagy via the mTOR pathway

SGK2通过mTOR通路抑制保护性自噬,从而介导单纯疱疹性角膜炎中的细胞凋亡。

阅读:1

Abstract

BACKGROUND: Herpes simplex virus type 1 (HSV-1) is a common human pathogen of herpes simplex keratitis (HSK), one of the leading causes of infectious blindness worldwide. Antiviral therapies remain limited by their dependence on active viral replication and rising drug resistance. This study aimed to explore the role of serum and glucocorticoid-regulated kinase 2 (SGK2) in regulating apoptosis and autophagy in HSV-1 infected corneal epithelial cells (CECs). METHODS: Human corneal epithelial cells (HCECs) and mouse corneas were infected with HSV-1 to evaluate HSV-1 replication and apoptosis. RNA sequencing of uninfected and HSV-1 infected HCECs was performed to identify differentially expressed genes associated with infection. SGK2 expression was assessed in vitro and in vivo via RT-qPCR, western blot, and immunofluorescence staining. SGK2 was pharmacologically inhibited with GSK 650,394, and genetically knocked down using shRNA, and autophagy was activated with rapamycin (RAPA). The regulatory roles of the SGK2/TSC2/mTOR pathway in apoptosis and autophagy were investigated using western blot, immunofluorescence staining, flow cytometry, and in cell western assay. RESULTS: HSV-1 infection significantly increased apoptosis and SGK2 expression in HCECs and mice CECs. Moreover, upregulation of SGK2 activated the mTOR pathway by promoting TSC2 protein degradation, thereby suppressing protective autophagy, enhancing apoptosis, and promoting HSV-1 replication. Treatment with the SGK2 inhibitor GSK 650,394 or shRNA-mediated SGK2 knockdown markedly attenuated these effects. Furthermore, the activation of autophagy with RAPA effectively suppressed HSV-1 induced apoptosis. CONCLUSIONS: These findings indicate that HSV-1 modulates host autophagy via the SGK2/TSC2/mTOR signaling axis to induce apoptosis in CECs, suggesting SGK2 as a potential molecular target for HSV-1 therapy.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。